Search the Newsreel

Zentalis Pharma Prices $80.5 Mln Offering Of Shares At $3.50 Per Share; Stock Down

(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage oncology company, priced a public offering of 23 million shares at $3.50 per share. The total gross proceeds from the offering are expected to be $80.5 million, and the company plans to use the net proceeds …

Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50

Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) has announced the pricing of an underwritten public offering of 23 million shares of common stock at $3.50 per share, aiming to raise approximately $80.5 million in gross proceeds. The offering is expected to close on August 17, 2026, with …

Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis

Barclays PLC has filed an amended Schedule 13G, disclosing a 3.17% beneficial ownership stake in Zentalis Pharmaceuticals Inc. (ZNTL), totaling 2,263,328 shares as of June 30, 2026. This filing indicates that Barclays now holds 5 percent or less of the class. The ownership includes …

Zentalis Pharmaceuticals stock falls on public offering news

Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) shares dropped 6.5% after announcing an underwritten public stock offering, which will include common stock and pre-funded warrants. The company plans to use the proceeds to fund clinical trials, preclinical studies, regulatory filings, and manufacturing for its oncology programs, particularly …

HC Wainwright Analysts Decrease Earnings Estimates for ZNTL

HC Wainwright analysts have reduced their Q3 2026 earnings per share estimates for Zentalis Pharmaceuticals (NASDAQ:ZNTL) to a loss of $0.63, down from $0.57. Despite this, the firm maintained a "Buy" rating and a $10 price target for the stock. Zentalis reported a Q2 …

Wedbush Adjusts Price Target on Zentalis Pharmaceuticals to $5 From $4, Maintains Neutral Rating

Wedbush has adjusted its price target for Zentalis Pharmaceuticals (ZNTL) to $5, an increase from the previous $4. The firm has decided to maintain its Neutral rating on the company's stock. This change reflects Wedbush's updated valuation for Zentalis Pharmaceuticals.

Zentalis Highlights Q2 Results and Azenosertib Progress

Zentalis Pharmaceuticals reported its Q2 2026 results and provided an update on the progress of azenosertib, its drug for Cyclin E1-positive platinum-resistant ovarian cancer. The company maintains a cash runway into late 2027 and is advancing its DENALI trial, aiming for an integrated topline …

Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $7.44, Implies 49% Upside

Analysts have raised the average 12-month price target for Zentalis Pharmaceuticals, Inc. (ZNTL) stock to $7.44, up from $7.22, with individual forecasts ranging from $4 to $11 per share. This updated target suggests a potential upside of approximately 49% from the August 6th closing …

Zentalis Pharmaceuticals, Inc. 2Q 2026: Net loss $(42.3M), EPS $(0.59) — 10-Q Summary

Zentalis Pharmaceuticals, Inc. reported a net loss of $(42.3M) and a diluted loss per share of $(0.59) for the second quarter of 2026, remaining a pre-revenue company. The company is advancing its clinical development for azenosertib, including a Phase 3 study and biomarker strategy, …

Renaissance Technologies LLC Lowers Position in Zentalis Pharmaceuticals, Inc. $ZNTL

Morgan Stanley Adjusts PT on Zentalis Pharmaceuticals to $5 From $4, Maintains Equalweight Rating

Morgan Stanley has increased its price target for Zentalis Pharmaceuticals (ZNTL) from $4 to $5, while reiterating an "Equalweight" rating on the stock. This adjustment reflects a modest upgrade in the firm's outlook for the clinical-stage biopharmaceutical company, which specializes in developing small molecule …

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings Results

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals announced its Q2 2026 financial results, reporting $174.6 million in cash, providing runway into late 2027. The company highlighted progress in its late-stage WEE1 inhibitor, azenosertib, for ovarian cancer, with the DENALI trial's accelerated approval strategy intact following FDA discussions. Topline data …

BlackRock, Inc. Expands Stake in Zentalis Pharmaceuticals (ZNTL) with Strategic Share Addition

BlackRock, Inc. has increased its stake in Zentalis Pharmaceuticals (ZNTL) by purchasing 2,441,077 additional shares, bringing its total ownership to 5.20% of the company's outstanding shares. This strategic move, executed at $4.85 per share, reflects BlackRock's confidence in the clinical-stage biopharmaceutical company's long-term prospects, …

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals announced that its Compensation Committee granted non-qualified stock options for 84,000 shares to two new employees. These grants were made under the 2022 Employment Inducement Incentive Award Plan, per Nasdaq Listing Rule 5635(c)(4), with an exercise price of $4.65 per share. The …

Zentalis Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview

Zentalis Pharmaceuticals Inc (ZNTL) is anticipated to report a loss of 49 cents per share in its upcoming earnings announcement. This information is based on an earnings preview from Refinitiv, providing investors with an expectation for the company's financial performance.

BlackRock (NYSE: BLK) discloses 5.2% ownership in Zentalis Pharmaceuticals (ZNTL)

BlackRock, Inc. has disclosed a 5.2% passive ownership stake in Zentalis Pharmaceuticals Inc. (ZNTL) through a Schedule 13G SEC filing. This includes 3,710,914 shares of common stock, with BlackRock holding sole voting power over 3,673,953 shares and sole dispositive power over all 3,710,914 shares. …

Zentalis Pharmaceuticals Inc (ZNTL) Institutional Confidence

Zentalis Pharmaceuticals Inc (ZNTL) has a strong institutional shareholding score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. Institutional ownership stands at 90.22%, a 37.20% increase quarter-over-quarter. James Simons is the largest institutional shareholder, holding 2.73% of outstanding shares.

Zentalis Pharmaceuticals Inc (ZNTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Zentalis Pharmaceuticals Inc (ZNTL), noting that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It briefly presents the company's stock price, market cap, and P/E TTM. The …

ZNTL|Zentalis Pharmaceuticals Inc|Price:4.445|Chg%:-0.055

Zentalis Pharmaceuticals Inc. (ZNTL) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for cancers, specifically azenosertib, a WEE1 inhibitor. Despite a strong stock market performance over the past month, the company's fundamentals and technicals are considered weak, with a "Buy" rating …

Rodman & Renshaw initiates Zentalis stock with buy on drug potential

Rodman & Renshaw initiated coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a buy rating and an $11.00 price target, citing the commercial potential of azenosertib, an investigational WEE1 inhibitor for platinum-resistant ovarian cancer. The firm believes the drug could receive accelerated approval if the DENALI …

ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?

Zentalis Pharmaceuticals (ZNTL) shares have surged 28% in the past three months, largely due to investor confidence in its lead oncology candidate, azenosertib, a WEE1 inhibitor targeting ovarian cancer and other tumor types. The company is advancing azenosertib through pivotal trials for platinum-resistant ovarian …

Should I buy Zentalis Pharmaceuticals (ZNTL)

ZNTL Jumps As Mizuho Targets Upside On Cancer Drug

Zentalis Pharmaceuticals Inc. (ZNTL) saw its stock jump by over 10% after Mizuho initiated coverage with an "Outperform" rating and an $8 price target, citing attractive risk-reward for its cancer drug azenosertib. The stock's surge was driven by expectations of key Phase 2 data …

Mizuho Securities Initiates a Buy Rating on Zentalis Pharmaceuticals (ZNTL)

Mizuho Securities has initiated a "Buy" rating for Zentalis Pharmaceuticals (ZNTL) with an $8.00 price target, based on analyst Graig Suvannavejh's assessment. Suvannavejh, known for a 21.5% average return on recommended stocks, covers the Healthcare sector. The broader analyst consensus for Zentalis Pharmaceuticals is …

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

Zentalis Pharmaceuticals announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026, highlighting overall survival data for azenosertib in platinum-resistant ovarian cancer from the DENALI Part 1b study with a rapid oral presentation. The company will also present a trial-in-progress poster …

Zentalis Pharmaceuticals Announces ESMO 2026 Rapid Oral Presentation of DENALI Overall Survival Data for Azenosertib in Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals announced that overall survival data from its DENALI Part 1b study of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer will be presented as a rapid oral presentation at the ESMO Congress 2026. This presentation highlights the potential for long-term survival benefits, supporting …

Mizuho Initiates Zentalis Pharmaceuticals at Outperform With $8 Price Target

Mizuho initiated coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with an Outperform rating and set an $8 price target. The firm highlighted Zentalis' strategic shift to focus on its WEE1 inhibitor, ZN-c3, in ovarian cancer. Mizuho believes that positive data from the Phase 3 ZN-c3 …